Atlas Trials

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Clinical trial NCT02318082 · COMPLETED

Trial details

NCT number
NCT02318082
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Versus Graft Host Disease
Start date
2015-02-01
Primary completion
2017-10-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.